IL6 and Castleman disease: As stated above, targeting IL-6 can been achieved by biological reagents, namely monoclonal antibodies directed against IL-6 itself such as siltuximab [81], which is approved for multicentric Castleman’s disease [82] and has shown efficacy in RA [83,84].